17

Mar2017
New CADTH Processes Expanding CADTH’s Drug Review Processes to Include Radiopharmaceuticals In collaboration with the participating jurisdictions, CADTH is pleased to announce that they will accept submissions for Radiopharmaceutical Submissions and Other Process Alignment Implementations effective April 1, 2017. Applicants/Submitters planning to file a submission or resubmission for a radiopharmaceutical on ... Read More

16

Mar2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of February 28, 2017: 33 negotiations are currently underway with 2 new files added since the last update of January 31, 2017: Eylea (aflibercept): Used to treat macular edema secondary to branch retinal vein ... Read More

15

Mar2017
CADTH is hosting an online or in person event on Tuesday, March 28, 2017 to release the fourth edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. The Guidelines are intended to help produce credible and standardized economic information that is relevant and useful to decision-makers in Canada’s ... Read More

15

Mar2017
INESSS Upcoming Meetings with Manufacturers – October 2017 “Liste des médicaments” INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the March 24, 2017 deadline for drugs to be listed on the October 2017 “Liste des médicaments". These meetings will be held between April ... Read More

17

Feb2017

PMPRB Form 3 Reminder

This is a reminder to all patentees of their filing requirements to the PMPRB respecting revenues and research and development expenditures. All patentees must submit their Form 3 information for 2016 by March 1, 2017. These filing requirements are contained in section 5 of the Patented Medicines Regulations. As part of their ... Read More

06

Feb2017
Kaitlyn Proulx appointed Managing Director / Directrice Générale Neil Palmer, Founder and Principal Consultant of PDCI Market Access Inc is pleased to announce the appointment of Kaitlyn Proulx as Managing Director.  As Managing Director, Kaitlyn manages PDCI’s operations and leads the firm’s pricing and market access consulting teams from PDCI’s headquarters ... Read More

06

Dec2016
On December 2, 2016, Health Canada released its updated guidelines for biosimilar biologic drug submissions.  The document will provide guidance to sponsors to enable them to satisfy the information and regulatory requirements for the authorization of biosimilars in Canada. The following criteria determine the scope if products that are eligible to ... Read More

02

Dec2016
As a first step to framework modernization, the Patented Medicines Prices Review Board (PMPRB) is undertaking major consultations regarding possible reform of its Compendium of Policies, Guidelines and Procedures, commonly referred to as “the Guidelines.” During Phase 1 of this consultation initiative, the PMPRB asked for input on how to rethink ... Read More

01

Dec2016
Effective December 1, 2016, all new Special Authorization requests for the treatment of Moderately to Severely Active Crohn's Disease and Fistulizing Crohn's Disease or Ulcerative Colitis for infliximab naive patients will be assessed for coverage with Inflectra. Remicade will not be approved for new infliximab starts for patients with the ... Read More

28

Nov2016
Effective November 30, 2016, the Ontario Public Drug Programs will begin funding INFLECTRA™ (infliximab) as a limited use benefit for the following new indications: LU Code 477 - For the treatment of ulcerative colitis in patients who meet clinical criteria. LU Code 478 - For the treatment of moderate to severe Crohn’s ... Read More